IXS - Innexus Biotechnology Inc (TSXV) - Page 2

Wow amazing shakedown after hitting over .70 today on huge volume.
WIll be interesting to see the direction tomorrow.

Volume a little lighter and some retail sellers showing up- Cormark has NOT got in on the buying again so far today. Could see some heavy buying start here today again , but anybody's guess as to where its going.
Longterm i think a great buy here - will be hearing more about their technology very soon i believe.

Amazed that IXS sold off after the DR LEVY news. One would think the stock would go up and not down .
Ronald Levy receives De Villiers International
Achievement Award
Honored for extraordinary contributiions that led to breakthrough targets for blood cancer treatment
The Leukemia & Lymphoma Society (LLS) has awarded its prestigious 2007 de Villiers International Achievement Award to noted cancer researcher Ronald Levy, MD, professor and chief of the division of oncology, at the Stanford University School of Medicine. The award is in recognition of Dr. Levy’s groundbreaking advances in the area of immunotherapies.

The award, named for the founders of LLS, will be presented to him at The LLS Update on ASH Conference at The San Francisco Hilton in San Francisco on Feb. 2, 2008.

“For over 30 years, Dr. Levy has received international acclaim for his work using the body's own arsenal to fight cancer,” said Louis DeGennaro, PhD, LLS Chief Scientific Officer. “His research holds promise for finding ways to control or perhaps even prevent these diseases.”

In the 1970s, Dr. Levy and his team used a new method of creating cells in the laboratory that churn out large quantities of antibodies that would specifically recognize and bind only to the cancer cells of a particular patient with B cell lymphoma, a cancer of the immune system.

The method worked, and some patients treated with these individualized antibodies were even cured. The scientists then discovered that a less-specific target found only on B cells also worked well for patients with B cell lymphoma without requiring analysis of each patient's tumor and unique drug production. In 1997, the resulting drug, Rituxan, became the first FDA-approved monoclonal antibody for cancer treatment. Currently, about 500,000 people each year receive the drug.

Dr. Levy, a researcher at the Stanford Cancer Center, continues to study lymphoma using the tools of immunology and molecular biology to develop a better understanding of how the disease develops and progresses. Some molecules present on the surface of lymphoma cells transmit signals that control lymphoma cell growth; these “receptors” include the immunoglobulin molecule on B cell tumors and the T cell receptor on T cell tumors. Dr. Levy is using these receptors as targets for lymphoma therapies.

Dr. Levy, a Harvard graduate, received his medical degree from Stanford. Over the span of his career, he has been the recipient of numerous cancer research awards, including a Specialized Center of Research (SCOR) grant, the LLS’s most ambitious and synergistic research initiative program. In 1982 he shared the first Armand Hammer Award for Cancer Research; the next year he received the Ciba-Geigy/Drew Award in Biomedical Research. In 1999 he received the American Society of Clinical Oncology Karnofsky Award and the prestigious General Motors Charles Kettering Prize. Most recently Dr. Levy has been awarded the Damashek Prize from the American Society of Hematology.

About the deVilliers International Achievement Award

The Leukemia & Lymphoma Society’s de Villiers International Achievement Award and grant was created in 1953 to recognize outstanding research contributions made to advance the treatment of prevention of leukemia, lymphoma, Hodgkin’s disease and myeloma. The award is named for the founders of the LLS, the de Villiers family, whose son, Robert died of cancer.

Bids building this morning and ask is very thin up to .40 - setting up for a nice pop at the open.
But this one i believe one to buy and put away -it has 10$ potential. JMHO

Made a good trade today getting rid of some at .405 up to .42 - bought back at .385 but only a partial fill- rats , come on down

Welll pulling back at days end so may end up filling again at the lower price.
really will look bullish tho with nearly 8 million traded and up a few%. Looks to me like it wil close in the .39 range.

Now 41.6 million shares have traded hands since the news release on the 7th of FEB- os shares are only 53.7 Million. The average price that was paid was .48, so most are in at much higher prices. Canaccord has been far and away the biggest dumpster - and one would have to believe they are running out of shares to dump.( or margin to short)
The reality is that Cormark and RBC buyers are accumulating and are in for the long haul - as well as some of us from TD.
I am hoping for a pullback on the open tomorrow to regain the size of position i had yesterday.

ANON, Jennings and NAT BAnk knocked her down to .365 this am- but now all 3 have turned tail and are on the buy- i think their shakedwon didnt work as well as planned- perhaps a bit of shorting- now at .39 x .395 and not much in the way above

Appears the buying pressure has let up - and so the selling begins , albeit very small volume - as the daytraders exit, take their lumps and move on to the next runner.

I dont know about the shortterm - i bought in for the longterm gains- as I said this one looks to be a multi$$ stock in the next year or two.
It appears I didnt choose the bottom as it was played down today by ANON and NAT bank, but will keep an eye and buy more lower if it drops below .30

Here it is, in a nutshell

IXS currently sports a market cap of about 18 million $$- 53 mil O/S at .34 .

Royalty Pharma bought 1 million $ worth of shares at $ 1.01 and also anted up another 4.5 Million for two royalty interests in IXS's first two products that will be going into testing. They will pay IXS up to another 30 million to buy increased interests in these same two products if certain conditions are met.

You total that up and you get $ 35.5 million in royalty payments in a relatively short time. THAT IS NEARLY DOUBLE thier current market valuation.

The market looks ahead and not backwards- there is no bluesky in their current valuation -which leads us to believe there is a long ways to run yet.

IXS has informed us that this is not the end of the products that will be going into testing- research and development will continue as this technology has far- reaching potential in a number of areas of treatment of disease .

But of course the blockbuster news was that their latest testing found that DXL625, targeting lymphoma, worked better that Rituxan - a mulit billion $ drug currently used .

This prompted the inventor of Rituxan, Dr. Ronald Levy, to join IXS's scientifc research team and IMO that provides a mountain of credibility to IXS's Dynamic Crosslinking superantibody technology.

IXS is one of those rare , once in a lifetime opportunities to get on at ground floor of one of those 1000% + gainers that you see in the biotech sector. Remember Imclone? Went from a dollar to over 84$ in less than two years.

This is one to put away for your retirement.

Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
2008-01-25 01:30 ET - News Release
First Phase III Study That Showed Symptom Improvement of Rituxan Plus Methotrexate in Biologic-Naïve RA Patients
SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. -- (Business Wire)

Genentech, Inc. (NYSENA) and Biogen Idec (Nasdaq:BIIB) announced today that a Phase III clinical study of Rituxan® (rituximab) in biologic-naïve patients met its primary endpoint of a significantly greater proportion of Rituxan-treated patients achieving an American College of Rheumatology (ACR) 20 response at week 24, compared to placebo. The study enrolled patients with moderately-to-severely active rheumatoid arthritis (RA) who had an inadequate response to prior treatment with methotrexate (MTX), a disease modifying antirheumatic drug (DMARD).

In this study, known as SERENE, patients who received a single treatment course of two infusions of either 500 mg or 1000 mg of Rituxan in combination with a stable dose of MTX displayed a statistically significant improvement in ACR20 scores compared to patients who received placebo in combination with MTX. Although the study was not designed to compare the Rituxan doses, treatment efficacy appears to be similar between both Rituxan doses. Further analyses of the data are ongoing and will be submitted for presentation at an upcoming medical meeting.

"While use of Rituxan with MTX is well-established in RA patients who have had an inadequate response to anti-TNF therapy, this is the first Phase III study demonstrating that Rituxan improved symptoms of RA in patients who had not previously been treated with a biologic therapy," said Hal Barron, M.D., Genentech's senior vice president, Development and chief medical officer. “These findings support the potential use of Rituxan earlier in the course of treatment for this debilitating disease.”

“These data provide further support for B-cell therapy in RA,” said Evan Beckman, M.D., Biogen Idec’s senior vice president of Immunology Research and Development. “We look forward to sharing the full analysis results from SERENE with the medical community and the FDA.”

A preliminary analysis of the data did not reveal any unexpected safety signals. The incidence of overall adverse events and serious adverse events were comparable between Rituxan and placebo treatment groups. The rates of overall infections and serious infections were comparable between Rituxan and placebo treatment groups. There were more infusion-related reactions with the first Rituxan infusion, which were primarily mild to moderate in severity and reversible with medical intervention. There were no serious infusion reactions with Rituxan. The companies continue to monitor the long-term safety of Rituxan treatment.

About the SERENE Study
SERENE is a Phase III, randomized, double-blind, placebo-controlled, parallel group, three-arm international study designed to evaluate the efficacy and safety of Rituxan plus MTX in patients with moderately-to-severely active RA who had an inadequate response to MTX monotherapy. A total of 509 randomized patients from 102 study sites across 11 countries received Rituxan (500 mg or 1000 mg) plus MTX or placebo plus MTX. The proportion of patients achieving an ACR20, the primary outcome measure, was assessed at week 24.
About RA
RA is a debilitating autoimmune disease that affects an estimated 1.3 million Americans and hinders daily activities. The damage that occurs in RA is a result of the immune system attacking joint tissue, causing painful chronic inflammation, irreversible destruction of cartilage, tendons and bones, which often results in disability. Common RA symptoms include inflammation of the joints, swelling, fatigue, stiffness and pain. Additionally, since RA is a systemic disease, it can affect other tissues such as the lungs and eyes.
About Rituxan
Rituxan, discovered by Biogen Idec, is a therapeutic antibody that first received Food and Drug Administration (FDA) approval in November 1997 for the treatment of relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL). It was also approved in the European Union under the trade name MabThera® in June 1998. In February 2006, Rituxan also received FDA approval in combination with MTX to reduce signs and symptoms in adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF-antagonist therapies. Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Rituxan does not target the entire immune system.

CD20 is not found on stem cells, pro-B cells (B-cell precursors), normal plasma cells, or other normal tissues.
Rituxan does not target stem cells in the bone marrow, and B-cells can usually regenerate and gradually return to normal levels after treatment with Rituxan.
Rituxan does not target plasma cells. These cells make antibodies that help fight infections.
In addition, Rituxan received FDA approval in September 2006 for first-line treatment of previously-untreated patients with follicular NHL in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy and also for the treatment of low-grade NHL in patients with stable disease or who achieve a partial or complete response following first-line treatment with CVP chemotherapy.

Rituxan is being studied in primary progressive multiple sclerosis, for which there is currently no FDA-approved therapy. Rituxan is also being studied in other autoimmune diseases with significant unmet medical needs, including systemic lupus erythematosus, lupus nephritis and antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis.

Genentech and Biogen Idec co-market Rituxan in the United States, and Roche markets MabThera in the rest of the world, except Japan, where Rituxan is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd. For a copy of the Rituxan full prescribing information, including Boxed Warning, please call 1-800-821-8590 or visit http://www.gene.com.

YOu can bet Genentech and Biogen are already looking at IXS for a possible buyout- after all DR LEVY already on board with IXS's scientific research team and has ties to both those major pharmas.